Interventional, Randomized, Double-blind, Parallel-group, Healthy Subject, Single Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab Manufactured Using Two Different Cell Lines

H. Lundbeck A/S1 site in 1 country84 target enrollmentSeptember 27, 2021

ConditionsHealthy Participants

InterventionsEptinezumab Mammalian Cell Line Eptinezumab Yeast Cell Line

DrugsEptinezumab Mammalian Cell Line Eptinezumab Yeast Cell Line

Overview

Phase: Phase 1
Intervention: Eptinezumab Mammalian Cell Line
Conditions: Healthy Participants
Sponsor: H. Lundbeck A/S
Enrollment: 84
Locations: 1
Primary Endpoint: Area Under the Eptinezumab Plasma Concentration-Time Curve (AUC) From Zero to Infinity (AUC0-inf)
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Eptinezumab is a preventive treatment for migraine. The drug is made from a process that currently uses yeast cells for production of the drug. The trial researchers want to test whether using a new production cell line to make eptinezumab will affect the way the drug behaves in the body. To do this, the researchers will give a single dose of eptinezumab to healthy participants. Some of the participants will get eptinezumab that has been made from yeast cells. Others will get eptinezumab made with the new cell line.

Registry

clinicaltrials.gov

Start Date

September 27, 2021

End Date

July 18, 2022

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

H. Lundbeck A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The participant has a body weight ≥50 and ≤100 kilograms (kg).
•The participant has a body mass index (BMI) ≥18.5 and ≤30 kg/meter (m\^2) at the screening visit and at the baseline visit.
•The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the screening visit and at the baseline visit.
•The participant has a resting supine systolic blood pressure ≥91 and ≤140 millimeters of mercury (mmHg) and a resting supine diastolic blood pressure ≥51 and ≤85 mmHg at the screening visit and at the baseline visit.
•The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, vital signs, an electrocardiogram (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.

Exclusion Criteria

•The participant has taken disallowed medication \<1 week prior to the dose of investigational medicinal product (IMP) or \<5 half-lives prior to the screening visit for any medication taken.
•The participant has taken any IMP \<3 months or \<5 half-lives (whichever is longer) prior to the first dose of IMP.
•The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder.
•The participant has been dosed with a monoclonal antibody (mAb) ≤6 months prior to the screening visit.
•The participant is a smoker or uses other nicotine-containing products (for example, snuff, nicotine patches, nicotine chewing gum, mock cigarettes, inhalers). Ex-smokers must have ceased smoking \>3 months prior to the screening visit.
•Other inclusion and exclusion criteria may apply.

Arms & Interventions

Eptinezumab Mammalian Cell Line

Participants will receive a single intravenous (IV) infusion of eptinezumab mammalian cell line on Day 1.

Intervention: Eptinezumab Mammalian Cell Line

Eptinezumab Yeast Cell Line

Participants will receive a single IV infusion of eptinezumab yeast cell line on Day 1.

Intervention: Eptinezumab Yeast Cell Line

Outcomes

Primary Outcomes

Area Under the Eptinezumab Plasma Concentration-Time Curve (AUC) From Zero to Infinity (AUC0-inf)

Time Frame: Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140

Secondary Outcomes

Percent Extrapolated AUC of Total AUC0-inf (AUC%extr)(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)
Maximal Observed Plasma Concentration (Cmax)(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)
Apparent Volume of Distribution (Vz)(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)
Systemic Clearance (CL), Defined as Dose/AUC0-inf(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)
Area Under the Plasma Concentration-Time Curve From Zero to Time t (AUC0-t)(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)
Apparent Terminal Elimination Half-Life (t½)(Day 1 (pre-dose up to 12 hours after the end of the infusion) up to Day 112 (after the end of the infusion), and at the follow-up visit Day 140)